Iylon Precision Oncology shared a post on LinkedIn:
“Studying Lung Cancer with Tiny Lab-Grown Tumors.
Lung cancer continues to be a major global health challenge, driving the need for more effective ways to study the disease and improve treatment outcomes. In recent years, researchers have turned to innovative laboratory models known as organoids, grown from patient tumor cells. These models closely mimic real tumors, allowing scientists to better understand how lung cancer develops, progresses, and responds to different therapies.
By using organoids, researchers can explore new drug targets, test potential treatments, and gain insights into how individual patients might respond to specific therapies. This approach is helping move cancer research toward more personalized and precise care.
The growing interest in organoid-based cancer modeling highlights its potential to transform how lung cancer is studied and managed, offering hope for more effective and tailored therapies in the years ahead.
The role of Organoid-based precision cancer modeling in Lung Cancer is explained in the following video link.
At Iylon Precision Oncology (www.iylon.com), we harness genetic insights to provide personalized, evidence-based recommendations, helping guide the right medicine, for the right patient, at the right dose, at the right time, and aimed at the right target.”
Other articles featuring Iylon Precision Oncology on OncoDaily.